









Markets
/
Stocks
/
nasdaq-cvm
/

CEL-SCI Corp

CVM

7.340USD

+0.280+3.97%

Close 11/05, 16:00（ET）Quotes delayed by 15 min

39.06MMarket Cap

LossP/E TTM



CEL-SCI Corp

7.340

+0.280+3.97%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Company

Financials

Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of CEL-SCI Corp

Currency: USD Updated: 2025-11-05

Key Insights

The company's fundamentals are relatively healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite a very weak stock market performance, the company shows strong technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

CEL-SCI Corp's Score

Industry at a Glance

Industry Ranking

141 / 407

Overall Ranking

276 / 4616

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 1 analysts

Buy

Current Rating

300.000

Target Price

+3558.54%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

CEL-SCI Corp Highlights

StrengthsRisks

CEL-SCI Corporation is a late clinical-stage biotechnology company. It is engaged in research and development directed at improving the treatment of cancer and other diseases by using the immune system, the body’s natural defense system. It is focused on the development of product candidates and technologies, including Multikine and Ligand Epitope Antigen Presentation System technology (LEAPS). Multikine (Leukocyte Interleukin, Injection), a true first-line cancer therapy, which is designed to help the immune system target the tumor at a time when the immune system is still relatively intact and thereby thought to be better able to mount an attack on the tumor. LEAPS is designed to stimulate the human immune system to more effectively fight bacterial, viral and parasitic infections as well as autoimmune conditions, allergies, transplantation rejection and cancer, when it cannot do so on its own. The LEAPS candidates include CEL-2000, CEL-4000 and DerG-PG275(Cit) (aka, CEL-5000).

Overvalued

The company’s latest PE is -0.80, at a high 3-year percentile range.

Institutional Buying

The latest institutional holdings are 669.31K shares, increasing 31.72% quarter-over-quarter.

Lower Market Activity

The company has less investor interest, with a 20-day turnover ratio of -0.76.

Financial Health

Currency: USD Updated: 2025-11-05

The company's current financial score is 5.93, which is lower than the Biotechnology & Medical Research industry's average of 6.92. Its financial status is stable, and its operating efficiency is low.

Score

Industry at a Glance

Previous score

5.93

Change



Financials

6.21

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

6.98

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

2.66

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

6.75

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.03

Key Metrics

Free cash flow

No Data

CEL-SCI Corp's Company Valuation

Currency: USD Updated: 2025-11-05

The company’s current valuation score is 7.16, which is higher than the Biotechnology & Medical Research industry's average of 7.05. Its current P/E ratio is -0.80, which is -95.83% below the recent high of -0.03 and -462.68% above the recent low of -4.52.

Score

Industry at a Glance

Previous score

7.16

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 141/407

No Data

Earnings Forecast

Currency: USD Updated: 2025-11-05

The company’s current earnings forecast score is 8.00, which is equal to the Biotechnology & Medical Research industry's average of 8.00. The average price target for CEL-SCI Corp is 300.00, with a high of 300.00 and a low of 300.00.

Score

Industry at a Glance

Previous score

8.00

Change

Support & Resistance

No Data

Analyst Rating

Based on 1 analysts

Buy

Current Rating

300.000

Target Price

+3558.54%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

521

Total

Median

Average

Company name

Ratings

Analysts

CEL-SCI Corp

CVM

CRISPR Therapeutics AG

CRSP

Ionis Pharmaceuticals Inc

IONS

argenx SE

ARGX

Intellia Therapeutics Inc

NTLA

IQVIA Holdings Inc

IQV

...

104

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-11-05

The company’s current price momentum score is 7.20, which is higher than the Biotechnology & Medical Research industry's average of 6.49. Sideways: Currently, the stock price is trading between the resistance level at 9.80 and the support level at 5.47, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

7.07

Change

0.13

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(3)

Neutral(3)

Buy(1)

Indicators

Value

Direction

MACD(12,26,9)

-0.433

Sell

RSI(14)

36.667

Neutral

STOCH(KDJ)(9,3,3)

34.005

Neutral

ATR(14)

0.734

Low Volatility

CCI(14)

-74.972

Neutral

Williams %R

66.227

Sell

TRIX(12,20)

-1.006

Sell

StochRSI(14)

100.000

Buy

Moving Average

Sell(4)

Neutral(0)

Buy(2)

Indicators

Value

Direction

MA5

7.044

Buy

MA10

7.860

Sell

MA20

8.704

Sell

MA50

9.444

Sell

MA100

7.603

Sell

MA200

4.230

Buy

Institutional Confidence

Currency: USD Updated: 2025-11-05

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Lincoln Alternative Strategies LLC

555.00K

The Vanguard Group, Inc.

Star Investors

183.21K

+133.58%

BlackRock Institutional Trust Company, N.A.

114.25K

+337.80%

Kersten (Geert R)

73.41K

+0.78%

MAI Capital Management, LLC

64.93K

+270.01%

BofA Global Research (US)

40.98K

+68201.67%

UBS Financial Services, Inc.

29.82K

+914.18%

Geode Capital Management, L.L.C.

25.92K

+3.27%

Osaic Holdings, Inc.

15.53K

+61.17%

Risk Assessment

Currency: USD Updated: 2025-11-05

The company’s current risk assessment score is 1.65, which is lower than the Biotechnology & Medical Research industry's average of 3.47. The company's beta value is 0.51. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.